This is a working overview of Lactam bridge, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-12-09 and is reviewed periodically as new material appears.
Identity and purity are established with orthogonal methods rather than a single test. Reverse-phase high-performance liquid chromatography with ultraviolet detection gives a purity figure by area normalization, while mass spectrometry confirms the expected molecular ion. Amino acid analysis or peptide mapping can detect sequence errors that a mass value alone would miss, and residual counterion content is sometimes measured separately. Common impurities include truncated sequences, oxidized residues, and deamidated products; reporting them individually is more informative than a single composite purity number.
Lyophilized peptide arrives as a white to off-white cake or powder and is normally held at minus twenty degrees Celsius or colder for extended periods. Short-term bench work at ambient temperature is tolerable for minutes, not hours, because the solid is hygroscopic and picks up moisture that promotes hydrolysis. Vials should stay in a desiccator or a sealed bag with desiccant, protected from light, since aromatic residues in the sequence are susceptible to photo-oxidation. Inventory records that note arrival date and storage location reduce the chance of using degraded material.
Reconstitution is usually performed with sterile water or a dilute acetic acid solution, and the choice of solvent affects both dissolution speed and final pH. Complete dissolution should be confirmed by visual inspection before any aliquot is taken, since undissolved particles can concentrate in the sampling volume. Repeated freeze-thaw cycles are the most common cause of gradual loss of purity, so dividing a stock into single-use aliquots at the first opportunity is standard practice. Working solutions kept refrigerated are generally used within days rather than weeks.
Compared with the related compound melanotan II, PT-141 shows markedly weaker activation of receptors tied to pigmentation. This difference stems from subtle structural variations that alter affinity distribution across receptor subtypes. Investigators propose that such selectivity produces a different side effect profile in specific applications. However, downstream consequences of prolonged receptor activation remain uncertain in the literature. Published studies do not fully agree on the duration of signaling pathway activity and the mechanisms of desensitization.
From a pharmacokinetic standpoint, the peptide is usually delivered by injection because oral bioavailability is very low; proteases in the digestive tract degrade it rapidly. After subcutaneous administration, plasma concentrations reach a peak within roughly one hour. Its elimination half-life is relatively short, with most reports placing it in the range of a few hours. Nasal formulations have also been examined, though absorption varies widely between individuals. Metabolism proceeds mainly through peptidase cleavage, and the resulting products are excreted by the kidneys.
PT-141 initiates cellular signaling by binding to specific subtypes within the melanocortin receptor family. These receptors belong to the G protein-coupled receptor superfamily, and activation raises intracellular cyclic adenosine monophosphate levels. This cascade ultimately influences neuronal circuits in the central nervous system that are associated with sexual desire and arousal. Research indicates the compound's action concentrates in hypothalamic regions rather than peripheral tissues, which helps explain some observed pharmacological features. The selectivity of receptor binding underlies its functional differences.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form |
| Solubility class | Soluble in water and DMSO | Dissolves readily |
| Typical storage temperature | -20 °C or lower | Long-term, desiccated |
| Standard purity method | Reverse-phase HPLC | Area normalization |
| Freeze-thaw guidance | Limit to three cycles | Aliquot in advance |
Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
The peptide contains seven amino acids arranged in a ring, closed by a lactam bridge between a side-chain acid and an amine. This cyclic constraint holds the backbone in a defined conformation and increases resistance to enzymatic breakdown relative to linear analogs. N-terminal acetylation and a C-terminal amide further protect the molecule from exopeptidases. The result is a compound with a comparatively long circulation time for a small peptide. Structural modification of the bridge alters receptor affinity, which is one reason analogs in this family differ in their subtype preferences.
Whether the behavioral effect originates centrally, peripherally, or through both remains an active question. Animal experiments using receptor antagonists and site-specific injections point toward hypothalamic melanocortin circuits as a key locus, but translating those findings to humans is not straightforward. Blood pressure changes observed in trials suggest a vascular component that may be peripherally mediated. The relationship between receptor occupancy and reported effect has not been mapped in humans, and no validated biomarker predicts response. This gap makes it difficult to explain individual variability on pharmacological grounds alone.
Routine characterisation of bremelanotide relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nm, where the peptide backbone absorbs. Mass spectrometry, typically in tandem mode with electrospray ionisation, confirms identity and supports quantification in biological matrices. Additional checks include amino acid analysis, peptide mapping after enzymatic digestion, and confirmation of the lactam bridge, since incomplete cyclisation produces a mass-shifted by-product. Purity values above 95 percent are common in reference-grade material, though reports vary in how strictly related substances are resolved from the parent peak.
The lyophilised solid is relatively stable when kept dry, protected from light and held at reduced temperature, commonly minus 20 degrees Celsius or lower for long-term storage. In solution the peptide is more vulnerable: tryptophan oxidation, hydrolysis of the lactam bridge and aggregation all become relevant over time, and the rate depends on pH, buffer composition and concentration. Repeated freeze-thaw cycles are generally avoided because they promote aggregation. Aqueous working solutions are typically prepared fresh or split into single-use aliquots to limit degradation before analysis.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
In humans, adipose tissue is located beneath the skin (subcutaneous fat), around internal organs (visceral fat), in bone marrow (yellow bone marrow), intermuscular (muscular system), and in the breast (breast tissue). Adipose tissue is found in specific locations, which are referred to as adipose depots. In addition to adipocytes, which comprise the highest percentage of cells within adipose tissue, other cell types are present, collectively termed stromal vascular fraction (SVF) of cells. SVF includes preadipocytes, fibroblasts, adipose tissue macrophages, and endothelial cells. Adipose tissue contains many small blood vessels. In the integumentary system, which includes the skin, it accumulates in the deepest level, the subcutaneous layer, providing insulation from heat and cold. Around organs, it provides protective padding. However, its main function is to be a reserve of lipids, which can be oxidised to meet the energy needs of the body and to protect it from excess glucose by storing triglycerides produced by the liver from sugars, although some evidence suggests that most lipid synthesis from carbohydrates occurs in the adipose tissue itself. Adipose depots in different parts of the body have different biochemical profiles. Under normal conditions, it provides feedback for hunger and diet to the brain.
Specific industries, such as the airline, healthcare and food industries, have special concerns. Due to rising rates of obesity, airlines face higher fuel-costs and pressures to increase seating-width. In 2000, the extra weight of passengers with obesity cost airlines US$275 million. The healthcare industry has invested in special facilities for handling patients with class III obesity, including special lifting equipment and bariatric ambulances. Litigation accusing restaurants of causing obesity increases restaurant costs. In 2005, the US Congress discussed legislation to prevent civil lawsuits against the food industry in relation to obesity; however, it did not become law. With the American Medical Association's 2013 classification of obesity as a chronic disease, it is thought that health-insurance companies will more likely pay for obesity treatment, counseling and surgery, and the cost of research and development of adipose-treatment pills or gene-therapy treatments should become more affordable if insurers help to subsidize their cost. The AMA classification is not legally binding, however, so health insurers still have the right to reject coverage for a treatment or procedure. In 2014, The European Court of Justice ruled that morbid obesity is a disability. The Court said that if an employee's obesity prevents "full and effective participation of that person in professional life on an equal basis with other workers", then it shall be considered a disability and that firing someone on such grounds is discriminatory.
Glucocorticoids such as cortisol affect carbohydrate, fat, and protein metabolism, and have anti-inflammatory, immunosuppressive, anti-proliferative, and vasoconstrictive effects. Anti-inflammatory effects are mediated by blocking the action of inflammatory mediators (transrepression) and inducing anti-inflammatory mediators (transactivation). Immunosuppressive effects are mediated by suppressing delayed hypersensitivity reactions by direct action on T-lymphocytes. Anti-proliferative effects are mediated by inhibition of DNA synthesis and epidermal cell turnover. Vasoconstrictive effects are mediated by inhibiting the action of inflammatory mediators such as histamine. Mineralocorticoids such as aldosterone are primarily involved in the regulation of electrolyte and water balance by modulating ion transport in the epithelial cells of the renal tubules of the kidney.
=== Effect of tobacco smoking and nicotine === There is a relationship between smoking tobacco and periodontal disease, wound healing and oral cancers. Nicotine, the major pharmacologically active ingredient in tobacco smoke, lessens a host's ability to defend against bacterial invasion induced by plaque. It is also the ingredient responsible for addiction. Tobacco smoking impairs phagocytic and chemotactic activities of leukocytes and impedes wound healing, specifically by affecting gingival blood flow. Cigarette smokers are more likely to experience destruction of the alveolar bone and periodontal ligament and are at a higher risk of developing periodontal disease. Nicotine and lipopolysaccharides synergistically induce the production of nitric oxide (NO) and PGE2, and increase inducible nitric oxide synthase (iNOS) and COX-2 expression in human periodontal ligament (hPDL) cells. At the cellular level, nicotine reduces the proliferation of red blood cells, macrophages, and fibroblasts and increases platelet adhesiveness. Macroscopically, this affects healing and tissue perfusion due to micro clot formation in the blood vessels. Nicotine also has a sympathomimetic action, stimulating epinephrine and norepinephrine release, which causes vasoconstriction and limits tissue perfusion. Nicotine jeopardises bone formation by inhibiting neovascularization and osteoblastic differentiation.
Sources: en.wikipedia.org
Parathyroid hormone is the principal regulator of serum calcium hemostasis. In response to subcutaneous doses of Preotact (100 micrograms), serum total calcium levels increase gradually and reach peak concentration at approximately 6 to 8 hours after dosing. In general, serum calcium levels return to normal within 24 hours.
The analyte is already in an ion form in the solution, and it is desorbed as the solvent evaporates. Acid-base transfer. If the solvent is a buffer solution, then the analyte can ionize by exchanging a proton with the buffer. This form of ionization is well-suited for LC-MS, since the liquid used in liquid chromatography already is a buffer solution. Plasmaspray ionization or filament-on operation. The solvent in the spray is electron-ionized by an energetic electron beam. The ionized solvent then chemically ionizes the analyte. In ESI, the solution enters a capillary held at a high voltage (usually 2-5 kV), producing an electrospray into a heated chamber against a counterflow of a drying gas (usually nitrogen). This evaporates solvent molecules. The charge density increases on a droplet as it evaporates, until the electrostatic energy overcomes the surface tension energy, exploding the droplet. This process repeats, ending with an ion stream without the solvent. The ionization can occur by:
Launched from LC-19 at Cape Kennedy Air Force Station, Florida, Gemini 4 was the first flight to be controlled by the new Mission Control Center at the Manned Spacecraft Center in Houston, Texas, which had to conduct three-shift operations due to the flight's long duration. The broadcast of the launch was itself historic. For the first time an international audience, from 12 European nations, could watch the lift-off on live television via the Early Bird satellite. Press interest, due to the satellite broadcast and the new center in Houston, proved to be so high that NASA had to lease buildings to accommodate the 1,100 print and broadcast journalists who requested accreditation. Flight control shifted from Cape Kennedy to Houston as soon as the vehicle cleared the launch tower. At liftoff, two roll transients caused by misalignment of the Titan first-stage engines occurred; these were quickly corrected by the autopilot. The fuel top-off umbilical failed to detach and was pulled loose when the booster had climbed about 27 feet (8.2 meters). A small oscillation in the pitch and yaw planes resulted from this. Performance of all launch vehicle systems was nearly nominal. Some modifications had been made to the guidance program on Gemini 4's booster to produce a less lofted flight trajectory and a lower altitude at booster engine cut-off (BECO) than on Gemini 3; these were generally successful despite a still somewhat lofted flight path. BECO occurred at T+152 seconds; second-stage engine cut-off (SECO) occurred at T+333 seconds.
Newsom campaigned on reducing the cost of health care and increasing access. He also indicated his support for creating a universal state health-care system. The budget passed in June 2019 expanded eligibility for Medi-Cal from solely undocumented minor children to undocumented young adults from ages 19 to 25. In 2021, Newsom signed legislation expanding Medi-Cal eligibility to undocumented residents over age 50. On June 30, 2022, he signed a $307.9 billion state budget that "pledges to make all low-income adults eligible for the state's Medicaid program by 2024 regardless of their immigration status." This budget would make California the first U.S. state to guarantee healthcare to all low-income undocumented immigrants, at a cost of $2.7 billion per year. Newsom was criticized in early 2022 for walking back from his support for universal health care and not supporting CalCare, Assembly Bill 1400, which would have instituted single-payer healthcare in California; critics suggested that opposition from business interests, which had donated large sums to Newsom and his party, had swayed his opinion. On July 6, 2022, Newsom signed Senate Bill 184, which established the Office of Health Care Affordability, with the stated goal to "develop data-informed policies and enforceable cost targets, with the ultimate goal of containing health care costs". In August 2022, Newsom vetoed Senate Bill 57 which sought to authorize jurisdictions to approve supervised injection sites. Newsom signed The Zacky Bill. In October 2023, Newsom vetoed a bill to cap co-pays for insulin at $35.
=== Fencing === The sport reached its peak during the 2020 and 2024 Olympic Games. Cheung Ka-long became a national icon by winning back-to-back gold medals in men's individual foil, while Vivian Kong secured gold in women's individual épée in Paris 2024.
Sources: en.wikipedia.org
Cold storage at minus twenty degrees Celsius or below is typical, with desiccant and protection from light. The solid form is far more stable than any solution.
Repeated freeze-thaw cycles, alkaline pH, and exposure to light or oxygen are the main drivers. Moisture uptake by the solid also matters.
Mass spectrometry provides the strongest single identity check by matching the observed molecular ion to the expected value. Chromatographic retention time alone is not sufficient.
It primarily activates specific subtypes in the melanocortin receptor family. These receptors are G protein-coupled and mediate signaling mainly within the central nervous system.